Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere, Lilly Ink PGx Test Alliance

NEW YORK (GenomeWeb News) – Nanosphere today said that has signed an agreement with Eli Lilly to develop pharmacogenetic assays that Lilly will use in its drug development efforts.

The Northbrook, Ill.-based molecular diagnostics developer said that it would develop the assays to run on its new Verigene SP system, which is a sample-to-result, bench-top, molecular diagnostics instrument. It is a random access system that does not require PCR amplification, said Nanosphere.

Terms of the alliance have not been disclosed.